RU2017120901A - Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии - Google Patents
Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии Download PDFInfo
- Publication number
- RU2017120901A RU2017120901A RU2017120901A RU2017120901A RU2017120901A RU 2017120901 A RU2017120901 A RU 2017120901A RU 2017120901 A RU2017120901 A RU 2017120901A RU 2017120901 A RU2017120901 A RU 2017120901A RU 2017120901 A RU2017120901 A RU 2017120901A
- Authority
- RU
- Russia
- Prior art keywords
- api
- flask
- plastic
- container
- tablet
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00178—Special arrangements of analysers
- G01N2035/00188—Special arrangements of analysers the analyte being in the solid state
- G01N2035/00198—Dissolution analysers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00465—Separating and mixing arrangements
- G01N2035/00495—Centrifuges
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00465—Separating and mixing arrangements
- G01N2035/00524—Mixing by agitating sample carrier
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Claims (32)
1. Способ проведения ВЭЖХ с высокой пропускной способностью, и указанный способ включает:
а) опускание контейнеров с предварительно взвешенными образцами в пластиковые колбы;
b) добавление раствора к каждому набору из контейнера и колбы через дозирующую насадку колбы;
c) взбалтывание каждого набора из пластиковой колбы, контейнера и раствора до растворения образца;
d) центрифугирование каждого набора из пластиковой колбы, контейнера и раствора;
е) загрузку аликвотного количества супернатанта, полученного на этапе центрифугирования, в колонку ВЭЖХ; и
f) запуск колонки с подвижной фазой.
2. Способ по п.1, в котором контейнеры из этапа а) представляют собой флаконы,
3. Способ по п.1, в котором пластиковые колбы из этапа а) представляют собой колбы из ПЭВП.
4. Способ по п.1, дополнительно включающий корреляцию результатов из способа по п.1 и PAT-измерений для непрерывного производства.
5. Способ по п.4, в котором непрерывное производство предназначено для получения фармацевтической композиции.
6. Способ по п. 5, в котором фармацевтическая композиция представляет собой таблетку.
7. Способ по п.6, в котором таблетка предназначена для лечения CFTR-опосредованного заболевания.
8. Способ по п.7, в котором CFTR-опосредованное заболевание представляет собой муковисцидоз (CF).
9. Способ по п.6, в котором таблетка содержит два АФИ.
10. Способ по п.9, в котором один АФИ является CF-корректирирующим средством.
11. Способ по п.9, в котором один АФИ является CF-потенцирующим средством.
12. Способ по п.9, в котором один АФИ является CF-корректирующим средством, и другой АФИ является CF-потенцирующим средством.
13. Способ по п.9, в котором один АФИ представляет собой
14. Способ по п.9, в котором один АФИ представляет собой
15. Способ по п.9, в котором один АФИ представляет собой
а другой АФИ представляет собой
16. Способ по п.15, в котором соединение
находится в форме 1, и
соединение
представляет собой по существу аморфное соединение в форме твердой дисперсии.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081181P | 2014-11-18 | 2014-11-18 | |
| US62/081,181 | 2014-11-18 | ||
| PCT/US2015/061264 WO2016081556A1 (en) | 2014-11-18 | 2015-11-18 | Process of conducting high throughput testing high performance liquid chromatography |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017120901A true RU2017120901A (ru) | 2018-12-19 |
| RU2017120901A3 RU2017120901A3 (ru) | 2019-04-02 |
| RU2691136C2 RU2691136C2 (ru) | 2019-06-11 |
Family
ID=54838411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120901A RU2691136C2 (ru) | 2014-11-18 | 2015-11-18 | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10302602B2 (ru) |
| EP (1) | EP3221692B1 (ru) |
| JP (1) | JP6494757B2 (ru) |
| KR (1) | KR102576006B1 (ru) |
| CN (1) | CN107110831B (ru) |
| AU (1) | AU2015350049B2 (ru) |
| BR (1) | BR112017010406B1 (ru) |
| CA (1) | CA2968130C (ru) |
| DK (1) | DK3221692T3 (ru) |
| ES (1) | ES2882656T3 (ru) |
| HR (1) | HRP20211194T1 (ru) |
| HU (1) | HUE055423T2 (ru) |
| IL (1) | IL252272B (ru) |
| MX (1) | MX2017006443A (ru) |
| PL (1) | PL3221692T3 (ru) |
| PT (1) | PT3221692T (ru) |
| RS (1) | RS62259B1 (ru) |
| RU (1) | RU2691136C2 (ru) |
| SG (1) | SG11201703963QA (ru) |
| SI (1) | SI3221692T1 (ru) |
| WO (1) | WO2016081556A1 (ru) |
| ZA (1) | ZA201703531B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白的调控剂 |
| SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
| JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態 |
| HUE036165T2 (hu) | 2006-04-07 | 2018-06-28 | Vertex Pharma | ATP-kötõ kazetta transzportereinek modulátorai |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA2795804C (en) | 2010-04-07 | 2021-10-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
| PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| AU2017371200B2 (en) | 2016-12-09 | 2021-05-06 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| KR20200097293A (ko) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
Family Cites Families (247)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758475A (en) | 1971-07-20 | 1973-09-11 | Sandoz Ag | Pyrido(2,3-d)pyrimidin 2 ones |
| EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
| IT1226048B (it) | 1981-12-14 | 1990-12-10 | Medea Res Srl | Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| EP0278374A3 (de) * | 1987-02-06 | 1989-03-01 | Pharmatest Apparatebau Gmbh | Vorrichtung zur Bestimmung der Wirkstoff-Freigabe von pharmazeutischen Produkten |
| US5981714A (en) | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
| JP3167762B2 (ja) | 1990-11-27 | 2001-05-21 | 武田薬品工業株式会社 | ピリドピリダジン誘導体およびその用途 |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| CA2107196A1 (en) | 1992-09-29 | 1994-03-30 | Mitsubishi Chemical Corporation | Carboxamide derivatives |
| US6060024A (en) * | 1993-07-14 | 2000-05-09 | Zymark Corporation | Automatic dissolution testing system |
| GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| JPH09504028A (ja) | 1993-10-21 | 1997-04-22 | ジー．ディー．サール アンド カンパニー | 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体 |
| DE4405712A1 (de) | 1994-02-23 | 1995-08-24 | Basf Ag | Substituierte Naphthyridine und deren Verwendung |
| RU2114844C1 (ru) | 1994-04-11 | 1998-07-10 | Санкио Компани Лимитед | Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний |
| BR9509036A (pt) | 1994-09-27 | 1997-10-14 | Janssen Pharmaceutica Nv | Derivados biciclicos de benzoato de peperidinila n-substituída |
| US6063260A (en) * | 1994-10-28 | 2000-05-16 | Neurosearch A/S | Patch clamp apparatus and technique having high throughput and low fluid volume requirements |
| US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
| US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| AU715658B2 (en) | 1996-04-03 | 2000-02-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DE69713402T2 (de) | 1996-08-23 | 2002-11-07 | Agouron Pharma | Liganden des neuropeptids y |
| JP2002511054A (ja) | 1996-12-30 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | ファルネシル蛋白トランスフェラーゼ阻害薬 |
| US5948814A (en) | 1997-02-20 | 1999-09-07 | The Curators Of The University Of Missouri | Genistein for the treatment of cystic fibrosis |
| WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
| BR9813019A (pt) | 1997-10-02 | 2000-09-05 | Sankyo Co | Derivados do ácido amidocarboxìlico, agentes para diminuir a glicose do sangue, redutor de lipìdio, para melhorar a resistência à insulina, anti-inflamatório, para imuno regulagem, para inibir a aldose reductase, para inibir a 5-lipoxigenase, para a geração de supressor de peróxido de lipìdio, para ativar a ppar, para minorar a osteoporose, e, composições para a terapia ou prevenção da diabete melito, da hiperlipemia, da obesidade, da tolerância à glicose prejudicada, da resistência à insulina que não a igt, do fìgado gorduroso, de complicações diabéticas, da arterioesclerose, da diabete melito gestacional, da sìndrome do ovário policìstico, da artroesteìte, da artrite reumática, de doenças alérgicas, da asma, do câncer, de doenças auto imunes, da pancreatite, e de cataratas |
| DE69914458T2 (de) | 1998-02-17 | 2004-10-28 | G.D. Searle & Co., Chicago | Verfahren zur enzymatischen auflösung von laktamen |
| CA2334298C (en) | 1998-06-08 | 2008-01-08 | Schering Corporation | Neuropeptide y5 receptor antagonists |
| US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| KR20010101287A (ko) | 1998-12-18 | 2001-11-14 | 블레어 큐. 퍼거슨 | 케모킨 수용체 활성의 조절자로서 ｎ-우레이도알킬-피페리딘 |
| ATE277905T1 (de) | 1999-02-24 | 2004-10-15 | Hoffmann La Roche | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten |
| CZ20013046A3 (cs) | 1999-02-24 | 2002-02-13 | F. Hoffmann-La Roche Ag | Fenylové a pyridinylové deriváty |
| AU772446B2 (en) | 1999-02-24 | 2004-04-29 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| EP1194417A1 (de) | 1999-06-18 | 2002-04-10 | Bayer Ag | Phenoxyfluorpyrimidine |
| UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
| WO2001046165A2 (en) | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
| NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7122309B2 (en) * | 2000-01-15 | 2006-10-17 | Avigenics, Inc. | High throughput screening assay for detecting a DNA sequence |
| WO2001054690A1 (en) | 2000-01-28 | 2001-08-02 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
| WO2001056989A2 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| US20010047100A1 (en) | 2000-04-26 | 2001-11-29 | Kjaersgaard Hans Joergen | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| WO2001083517A1 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Stat4 and stat6 binding dipeptide derivatives |
| US6499984B1 (en) | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
| WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| DE60120193T2 (de) | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| US20020115619A1 (en) | 2000-10-04 | 2002-08-22 | Rubenstein Ronald C. | Compositions and methods for treatment of cystic fibrosis |
| GB2367816A (en) | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
| ATE269856T1 (de) | 2000-10-20 | 2004-07-15 | Merck Patent Gmbh | Chirale binaphtol-verbindungen |
| US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
| JP4323802B2 (ja) | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
| US6962674B2 (en) * | 2001-02-28 | 2005-11-08 | Varian, Inc. | Dissolution test apparatus |
| EP1383799A4 (en) | 2001-04-10 | 2008-08-06 | Transtech Pharma Inc | PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS |
| CA2444395C (en) | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| CA2448198A1 (en) | 2001-05-22 | 2002-12-05 | Neurogen Corporation | 5-substituted-2-arylpyridines as crf1 modulators |
| US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| JP2005508904A (ja) | 2001-09-11 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体 |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| JP2003221386A (ja) | 2001-11-26 | 2003-08-05 | Takeda Chem Ind Ltd | 二環性誘導体、その製造法およびその用途 |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| JP2006505571A (ja) | 2002-10-15 | 2006-02-16 | リゲル ファーマシューテイカルズ、インコーポレイテッド | 置換されたインドール及びｈｃｖ阻害剤としてのその使用 |
| CA2503713A1 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity |
| US6976384B2 (en) * | 2002-10-31 | 2005-12-20 | Nanostream, Inc. | Parallel detection chromatography systems |
| MXPA05006367A (es) | 2002-12-12 | 2005-08-29 | Pharmacia Corp | Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno. |
| WO2004063179A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
| NZ542153A (en) | 2003-02-10 | 2009-01-31 | Vertex Pharma | Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| EP1601657A1 (en) | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazole modulators of atp-binding cassette transporters |
| AU2004236173B2 (en) | 2003-04-30 | 2008-07-03 | The Institutes For Pharmaceutical Discovery, Llc | Substituted carboxylic acids |
| WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| CA2530075C (en) | 2003-06-27 | 2012-08-21 | Harvey Pollard | Amphiphilic pyridinium compounds, method of making and use thereof |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| JP2005053902A (ja) | 2003-07-18 | 2005-03-03 | Nippon Nohyaku Co Ltd | フェニルピリジン類、その中間体及びこれを有効成分とする除草剤 |
| WO2005023806A2 (en) | 2003-09-05 | 2005-03-17 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
| ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| WO2005035514A2 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| FR2861304B1 (fr) | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| AU2004290581B2 (en) | 2003-11-14 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters |
| JP2007511572A (ja) | 2003-11-19 | 2007-05-10 | グラクソ グループ リミテッド | 統合失調症治療のためのシクロオキシゲナーゼ−２選択的阻害剤の使用 |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CN1938279B (zh) | 2004-01-30 | 2011-09-14 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白调控剂 |
| US7691860B2 (en) | 2004-02-19 | 2010-04-06 | Banyu Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
| US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| JP2007533740A (ja) | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Ｂａｃｅ阻害剤としてのアミド |
| EP1766062A4 (en) | 2004-06-01 | 2008-07-09 | Tm Bioscience Corp | METHOD FOR DETECTING MUTATIONS ASSOCIATED WITH CYSTIC FIBROSIS |
| TWI428271B (zh) * | 2004-06-09 | 2014-03-01 | Smithkline Beecham Corp | 生產藥物之裝置及方法 |
| US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白的调控剂 |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CA2572549A1 (en) | 2004-07-01 | 2006-01-12 | Warner-Lambert Company Llc | Preparation of pharmaceutical compositions containing nanoparticles |
| WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
| MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
| WO2006037117A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ATE540935T1 (de) | 2004-10-12 | 2012-01-15 | Astrazeneca Ab | Chinazolinderivate |
| WO2006051394A1 (en) | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
| NZ555502A (en) | 2004-12-15 | 2010-12-24 | Dompe Pha R Ma Spa Res & Mfg | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| JP4790260B2 (ja) | 2004-12-22 | 2011-10-12 | 出光興産株式会社 | アントラセン誘導体を用いた有機エレクトロルミネッセンス素子 |
| KR101276987B1 (ko) * | 2005-01-25 | 2013-06-25 | 바이엘 크롭사이언스 아게 | 아인산, 포세틸-ａｌ 또는 두 가지 모두의 동시적 분석방법 |
| US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
| US7888374B2 (en) | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| JPWO2006082952A1 (ja) | 2005-02-01 | 2008-06-26 | 武田薬品工業株式会社 | アミド化合物 |
| EP2363128B1 (en) | 2005-03-11 | 2016-02-17 | Vertex Pharmaceuticals Incorporated | Indole modulators of ATP-binding cassette transporters |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| AR053712A1 (es) | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
| CA2605300A1 (en) | 2005-04-19 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| AU2006251624A1 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| MX2007015002A (es) | 2005-06-02 | 2008-02-15 | Bayer Cropscience Ag | Derivados de heteroarilo sustituidos con fenilalquilo. |
| WO2006136829A2 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
| CN2856973Y (zh) * | 2005-07-25 | 2007-01-10 | 中国环境科学研究院 | 旋转振荡装置 |
| TW200738331A (en) * | 2005-07-26 | 2007-10-16 | Showa Denko Kk | Method for analyzing low-molecular-weight compound in sample containing water-soluble polymer and low-molecular-weight compound |
| WO2007021982A2 (en) | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN101287732A (zh) | 2005-08-11 | 2008-10-15 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜电导调节剂的调控剂 |
| EP1928886B1 (en) | 2005-09-09 | 2011-04-13 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
| ES2335922T3 (es) | 2005-09-23 | 2010-04-06 | F.Hoffmann-La Roche Ag | Nueva formulacion de dosificacion. |
| CN101312722A (zh) | 2005-10-06 | 2008-11-26 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白的调控剂 |
| AR056875A1 (es) | 2005-10-19 | 2007-10-31 | Gruenenthal Gmbh | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos |
| SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
| US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| WO2007054480A1 (en) | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
| CN101326182B (zh) | 2005-12-05 | 2011-09-28 | 史密丝克莱恩比彻姆公司 | 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂 |
| JP2009521468A (ja) | 2005-12-24 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体 |
| WO2007075946A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態 |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CN103214450B (zh) | 2005-12-28 | 2016-10-05 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物 |
| US8158059B2 (en) * | 2005-12-30 | 2012-04-17 | Sotax Corporation | Integrated dissolution processing and sample transfer system |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| HUE036165T2 (hu) | 2006-04-07 | 2018-06-28 | Vertex Pharma | ATP-kötõ kazetta transzportereinek modulátorai |
| CA2652072A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP1882948A2 (de) * | 2006-07-28 | 2008-01-30 | Qiagen GmbH | Vorrichtung zur Probenverarbeitung |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| NZ576642A (en) | 2006-11-03 | 2011-11-25 | Vertex Pharma | Azaindole derivatives as cftr modulators |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| WO2008065068A2 (en) | 2006-11-27 | 2008-06-05 | Novartis Ag | Substituted dihydroimidazoles and their use in the treatment of tumors |
| CN101206205B (zh) * | 2006-12-22 | 2011-08-10 | 中国科学院大连化学物理研究所 | 微流量液相色谱在线大体积进样的方法和专用装置 |
| CN101209399B (zh) * | 2006-12-27 | 2010-07-28 | 中国科学院沈阳应用生态研究所 | 一种往复式振荡机样品安放与固定装置 |
| CN101210906A (zh) * | 2006-12-29 | 2008-07-02 | 电子科技大学 | 高通量自动化药物筛选实验检测*** |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒのモジュレーター |
| ES2548292T3 (es) | 2007-05-25 | 2015-10-15 | Vertex Pharmaceuticals Incorporated | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| CA2696298C (en) | 2007-08-24 | 2016-09-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
| WO2009036412A1 (en) | 2007-09-14 | 2009-03-19 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2008301907B2 (en) | 2007-09-14 | 2014-02-20 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| FR2921657A1 (fr) | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| EP2217572B1 (en) | 2007-11-16 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
| DE102007058718A1 (de) * | 2007-12-06 | 2009-06-10 | Erweka Gmbh | Vorrichtung und Verfahren zur automatischen Freisetzung und Messung von Wirkstoffen aus einer Arzneizubereitung |
| WO2009076142A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| EP2237768A2 (en) | 2007-12-07 | 2010-10-13 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| WO2009073757A1 (en) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| CN101925603B (zh) | 2007-12-13 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
| US20090173146A1 (en) * | 2008-01-07 | 2009-07-09 | Matthias Pursch | Temperature programmed low thermal mass fast liquid chromatography analysis system |
| CA3039943C (en) | 2008-02-28 | 2021-07-13 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| EP2257356B1 (en) * | 2008-02-29 | 2016-12-14 | Waters Technologies Corporation | Chromatography-based monitoring and control of multiple process streams |
| SI2615085T1 (sl) | 2008-03-31 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Piridilni derivati kot cftr-modulatorji |
| GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
| WO2010019239A2 (en) | 2008-08-13 | 2010-02-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8716338B2 (en) | 2008-09-29 | 2014-05-06 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| PL2358680T3 (pl) | 2008-10-23 | 2013-08-30 | Vertex Pharma | Stałe postacie N-(4-(7-azabicyklo[2.2.1]heptan-7-ylo)-2-(trifluorometylo)fenylo)-4-okso-5-(trifluorometylo)-1,4-dihydrochinolino-3-karboksyamidu |
| CA2742042A1 (en) | 2008-10-23 | 2010-04-29 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| BRPI0919930A2 (pt) | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
| JP2012507712A (ja) * | 2008-10-31 | 2012-03-29 | バイオメリュー・インコーポレイテッド | 分光法を使用した微生物の分離、キャラクタリゼーションおよび／または同定方法 |
| AU2008363828B2 (en) | 2008-11-06 | 2016-09-08 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| UA104876C2 (ru) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
| JP5699090B2 (ja) | 2008-12-30 | 2015-04-08 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター |
| EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| PL2408749T3 (pl) | 2009-03-20 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Modulatory transbłonowego regulatora przewodnictwa mukowiscydozy |
| JP2012525895A (ja) | 2009-05-07 | 2012-10-25 | ジーイーエイ・ファーマ・システムズ・リミテッド | 錠剤の製造モジュール及び錠剤の連続製造方法 |
| US8053866B2 (en) | 2009-08-06 | 2011-11-08 | Freescale Semiconductor, Inc. | Varactor structures |
| NZ598277A (en) | 2009-09-17 | 2014-03-28 | Vertex Pharma | Process for preparing azabicyclic compounds |
| EP2486571A1 (en) * | 2009-10-08 | 2012-08-15 | GE Healthcare UK Limited | Chromatography components |
| EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| WO2011050220A1 (en) | 2009-10-23 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| RU2553989C2 (ru) | 2009-10-23 | 2015-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза |
| CN201586570U (zh) * | 2010-02-03 | 2010-09-22 | 兰州大学 | 塑料离心过滤管 |
| EP2547658A1 (en) | 2010-03-19 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| AU2011230508B2 (en) | 2010-03-25 | 2016-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihyderoxypropyl)-6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA2795748C (en) | 2010-04-07 | 2020-12-08 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CA2795804C (en) | 2010-04-07 | 2021-10-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| AU2011242452A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| NZ603044A (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| KR20130056244A (ko) | 2010-04-22 | 2013-05-29 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
| TW201202250A (en) | 2010-05-20 | 2012-01-16 | Vertex Pharma | Processes for producing modulators of cystic fibrosis transmembrane conductance regulator |
| EP2575814A1 (en) | 2010-05-20 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| CN103153287A (zh) | 2010-08-23 | 2013-06-12 | 弗特克斯药品有限公司 | (R)-1-(2，2-二氟苯并[d][1，3]间二氧杂环戊烯-5-基)-N-(1-(2，3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用 |
| AU2011293135A1 (en) | 2010-08-27 | 2013-04-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| CN102058889A (zh) | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| KR101387872B1 (ko) | 2011-05-11 | 2014-04-22 | 경상대학교산학협력단 | 생물 검체 내 카페인 및 카테킨을 동시분석하는 방법 |
| CN102507770A (zh) * | 2011-10-25 | 2012-06-20 | 中国检验检疫科学研究院 | 检测化妆品中六氯酚的高效液相色谱法 |
| AU2012332225A1 (en) | 2011-11-02 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases |
| US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
| KR101985044B1 (ko) | 2011-11-08 | 2019-05-31 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절제 |
| CA3128556A1 (en) | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| JP2013253790A (ja) * | 2012-06-05 | 2013-12-19 | Chube Univ | ニバレノールの分析法 |
| WO2013185112A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
| WO2014014841A1 (en) | 2012-07-16 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| CN102788834B (zh) * | 2012-08-29 | 2015-06-03 | 浙江农林大学 | 水果可溶性糖快速测定方法 |
| KR101455694B1 (ko) | 2012-09-18 | 2014-11-03 | 학교법인 선목학원 | 에틸아세테이트 및 아세토니트릴의 유기용매 혼합액을 이용한 액체-액체 추출법을 포함하는 약물 검출법 |
| US20140092376A1 (en) | 2012-10-01 | 2014-04-03 | Momentive Performance Materials, Inc. | Container and method for in-line analysis of protein compositions |
| MX368353B (es) | 2012-11-02 | 2019-09-30 | Vertex Pharma | Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por cftr. |
| US9636301B2 (en) * | 2012-12-04 | 2017-05-02 | Arbutus Biopharma Corporation | In vitro release assay for liposome encapsulated vincristine |
| US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| CN103264029B (zh) * | 2013-05-06 | 2015-03-25 | 深圳市华星光电技术有限公司 | 一种色谱分析样品瓶清洗装置及清洗方法 |
| CN103743826B (zh) * | 2013-08-28 | 2015-12-02 | 合肥久诺医药科技有限公司 | 一种阿齐沙坦的高效液相色谱分析方法 |
| CN103822976B (zh) * | 2013-10-15 | 2015-05-27 | 辽宁省食品药品检验所 | 一种测定化妆品中4-甲氧基水杨酸钾的方法 |
| PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| CN104090038B (zh) * | 2014-07-07 | 2015-09-30 | 黄宏南 | 一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法 |
| CN104122345B (zh) * | 2014-07-31 | 2015-08-12 | 国家烟草质量监督检验中心 | 烟用纸中1,1,1-三羟甲基丙烷的测定方法 |
| CN104122346B (zh) * | 2014-07-31 | 2016-03-16 | 国家烟草质量监督检验中心 | 一种水基胶中尿素含量的测定方法 |
| NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
| MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
| WO2016087665A2 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
| JP6662885B2 (ja) | 2015-01-26 | 2020-03-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | カルボン酸生物学的等価体としてのテトラゾロン |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| CN105890945A (zh) * | 2016-04-01 | 2016-08-24 | 中国热带农业科学院分析测试中心 | 超声离心渗液进样快速测定土壤中速效钾的方法 |
-
2015
- 2015-11-18 PT PT158077248T patent/PT3221692T/pt unknown
- 2015-11-18 ES ES15807724T patent/ES2882656T3/es active Active
- 2015-11-18 SG SG11201703963QA patent/SG11201703963QA/en unknown
- 2015-11-18 RS RS20210992A patent/RS62259B1/sr unknown
- 2015-11-18 JP JP2017526627A patent/JP6494757B2/ja active Active
- 2015-11-18 BR BR112017010406-7A patent/BR112017010406B1/pt active IP Right Grant
- 2015-11-18 EP EP15807724.8A patent/EP3221692B1/en active Active
- 2015-11-18 MX MX2017006443A patent/MX2017006443A/es unknown
- 2015-11-18 WO PCT/US2015/061264 patent/WO2016081556A1/en active Application Filing
- 2015-11-18 RU RU2017120901A patent/RU2691136C2/ru active
- 2015-11-18 CA CA2968130A patent/CA2968130C/en active Active
- 2015-11-18 KR KR1020177016301A patent/KR102576006B1/ko active IP Right Grant
- 2015-11-18 HU HUE15807724A patent/HUE055423T2/hu unknown
- 2015-11-18 PL PL15807724T patent/PL3221692T3/pl unknown
- 2015-11-18 AU AU2015350049A patent/AU2015350049B2/en active Active
- 2015-11-18 US US15/526,885 patent/US10302602B2/en active Active
- 2015-11-18 CN CN201580073668.1A patent/CN107110831B/zh active Active
- 2015-11-18 DK DK15807724.8T patent/DK3221692T3/da active
- 2015-11-18 SI SI201531685T patent/SI3221692T1/sl unknown
-
2017
- 2017-05-14 IL IL252272A patent/IL252272B/en active IP Right Grant
- 2017-05-23 ZA ZA201703531A patent/ZA201703531B/en unknown
-
2021
- 2021-07-26 HR HRP20211194TT patent/HRP20211194T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017120901A3 (ru) | 2019-04-02 |
| JP2018502285A (ja) | 2018-01-25 |
| AU2015350049A1 (en) | 2017-06-08 |
| AU2015350049B2 (en) | 2021-08-19 |
| KR20170084272A (ko) | 2017-07-19 |
| RU2691136C2 (ru) | 2019-06-11 |
| BR112017010406B1 (pt) | 2021-03-09 |
| CN107110831B (zh) | 2020-02-21 |
| IL252272B (en) | 2020-11-30 |
| RS62259B1 (sr) | 2021-09-30 |
| NZ731893A (en) | 2023-09-29 |
| PL3221692T3 (pl) | 2021-12-06 |
| SI3221692T1 (sl) | 2021-11-30 |
| ZA201703531B (en) | 2019-11-27 |
| PT3221692T (pt) | 2021-09-10 |
| CA2968130A1 (en) | 2016-05-26 |
| WO2016081556A1 (en) | 2016-05-26 |
| US20170356885A1 (en) | 2017-12-14 |
| SG11201703963QA (en) | 2017-06-29 |
| US10302602B2 (en) | 2019-05-28 |
| HRP20211194T1 (hr) | 2021-10-29 |
| HUE055423T2 (hu) | 2021-11-29 |
| JP6494757B2 (ja) | 2019-04-03 |
| CN107110831A (zh) | 2017-08-29 |
| EP3221692B1 (en) | 2021-06-23 |
| ES2882656T3 (es) | 2021-12-02 |
| BR112017010406A2 (pt) | 2017-12-26 |
| IL252272A0 (en) | 2017-07-31 |
| MX2017006443A (es) | 2017-09-11 |
| DK3221692T3 (da) | 2021-08-23 |
| EP3221692A1 (en) | 2017-09-27 |
| CA2968130C (en) | 2022-08-16 |
| KR102576006B1 (ko) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017120901A (ru) | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии | |
| JP2018502285A5 (ru) | ||
| PE20200148A1 (es) | Anticuerpos anti-trem2 y metodos para utilizarlos | |
| EA201792045A1 (ru) | Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr | |
| MX2018013182A (es) | Materiales isoporosos cargados para separaciones electrostaticas. | |
| ES2551809A1 (es) | Máquina de preparación de sustancias de aplicación intravenosa | |
| FR3044001B1 (fr) | Procede de preparation d'un materiau adsorbant comprenant une etape de malaxage basique et procede d'extraction de lithium a partir de solutions salines utilisant ledit materiau | |
| RU2014133367A (ru) | Усовершенствованный способ получения микрогранул | |
| RU2016108842A (ru) | Система одноразового использования для опорожнения емкостей с жидкостью | |
| RU2019111152A (ru) | Новый способ стабилизации биофармацевтического лекарственного продукта при производстве | |
| JP2014528896A5 (ru) | ||
| MX2017005650A (es) | Composicion de antigeno para detectar enfermedad de chagas. | |
| MA51198A (fr) | Liants deshydrates, sous forme solide, leur procede d'obtention et leur procede de rehydratation | |
| RU2016148598A (ru) | Способ лиофилизации генно-терапевтического препарата, представляющего собой комплекс плазмидной ДНК и блок-сополимера ПЭГ-ПЭИ (полиэтилгликоль-полиэтиленимин) | |
| MX2016010596A (es) | Sedimentador de columna para la separacion de fases liquido/liquido de alto redimiento en procesos hidromelurciales y metodos de los mismos. | |
| EA201991594A1 (ru) | Депо-препарат | |
| EP3498263A4 (en) | STABLE LIQUID PHARMACEUTICAL PREPARATION FOR ANTI-INFLUENZA VIRUS ANTIBODIES | |
| Zhang et al. | Density Functional Study on [3+ 2]-Dipolar Cycloaddition Reaction of the N-heterocyclic Carbene Boryl Azide with Olefins. | |
| Skor et al. | Quantitative bioanalysis by microflow LC–MS to support discovery-based pharmacokinetic studies | |
| LIU et al. | Quantitative analysis of gemigliptin tartrate sesquihydrate by 19F quantitative NMR (19F-qNMR) | |
| RU2017102352A (ru) | Способ конвективного обезвоживания высокодисперсных биологически активных материалов | |
| ES2693540T3 (es) | Extracción de oro con disolventes | |
| Del Valle Lladser et al. | Supercritical CO2 extraction of solids using aqueous ethanol as static modifier is a two-step mass transfer process | |
| EA202191373A1 (ru) | Фармацевтическая композиция и способ ее получения | |
| Xingtao et al. | Application of Multimedia Technology in Chemical Experimental Teaching |